Author:
DeStefano Christin B.,Gibson Steven J.,Sperling Adam S.,Richardson Paul G.,Ghobrial Irene,Mo Clifton C.
Funder
GlaxoSmithKline
National Cancer Institute
Reference86 articles.
1. National Cancer Institute. Cancer stat facts: myeloma 2020 Accessed from: https://seer.cancer.gov/statfacts/html/mulmy.html, Accessed date December 1, 2020.
2. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma;Richardson;Blood,2010
3. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial;Durie;Lancet,2017
4. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma;O'Donnell;Br J Haematol,2018
5. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?;Kazandjian;Br J Haematol,2020
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献